ENDE
lucullus
 
 

Seraccess® - Disruptive technology for the monitoring and control of critical blood parameters

 

In its MedTech division, Securecell is developing Seraccess, an innovative technology for the fully automated, high-frequency automatic on-line collection, processing, and analysis of minute quantities of blood for the monitoring and control of critical blood parameters.

 
 

Seraccess® innovation roadmap

 

The Seraccess® innovation roadmap leads from the fully automated, highly accurate and precise monitoring of critical blood parameters in the ICU setting via a wearable semi-miniaturized to a fully miniaturized artificial pancreas device for unprecedented glucose control.

 
Company
 
 

Seraccess® Automated Glucose Monitoring (AGM) for Hospital Care

Seraccess® AGM - Automated and regular glucose measurement for the monitoring, detection, and treatment of dysglycemia

 
 
Company
 
 

Seraccess® Artificial Pancreas Device System (APDS) ONE

Seraccess® ONE - Breakthrough wearable Artificial Pancreas Device System for patients suffering from severe glycemic dysregulation.

 
 
Company
 
 

Seraccess® Artificial Pancreas Device System (APDS) NExtra

Seraccess® NEXTRA radically transforms diabetes treatment for patients suffering from moderate to severe glycemic dysregulation.

 
 
 

Contact us

 

Don’t miss this unique opportunity to invest in the future of diabetes treatment. Contact us now to get more informations.

 
 

Seraccess® is a mid-stage venture project of Securecell that offers investment opportunities to private and institutional investors.

 

All information and opinions contained herein have been prepared by management and its advisors and represent their assessment as of January 2022. No representation or warranty, expressed or implied, is given as to the accuracy or completeness of the contents, opinions, or projections expressed herein and no responsibility or liability is accepted. All information videos and contents do not constitute an offer to purchase securities. The website content does not constitute an invitation to buy shares under US or international law.